Funding

This research was supported by the National Natural Science Foundation of China (8190335).
Data availability statement
The data underlying this article are available in the FDA adverse events reporting system (FAERS). The datasets were derived from sources in the public domain: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
Ethics statement
The Medical Research Ethics Review Committee of the First Affiliated Hospital of Chongqing Medical University decided to waive the original ethic application procedure, based on the reason that the open public database used in this project.
References
1. Roizman, B., Whither herpesviruses? Adv Exp Med Biol, 1990.278 : p. 285-91.
2. Crimi, S., et al., Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data. Viruses, 2019. 11 (5).
3. Abb, J., [Prevention and therapy of herpesvirus infections]. Zentralbl Bakteriol Mikrobiol Hyg B, 1985.180 (2-3): p. 107-20.
4. Grinde, B., Herpesviruses: latency and reactivation - viral strategies and host response. J Oral Microbiol, 2013. 5 .
5. Verweij, M.C., et al., Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution. PLoS Pathog, 2015. 11 (4): p. e1004743.
6. Griffin, B.D., M.C. Verweij, and E.J. Wiertz, Herpesviruses and immunity: the art of evasion. Vet Microbiol, 2010. 143 (1): p. 89-100.
7. Elion, G.B., et al., Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A, 1977. 74 (12): p. 5716-20.
8. van Diemen, F.R. and R.J. Lebbink, CRISPR/Cas9, a powerful tool to target human herpesviruses. Cell Microbiol, 2017. 19 (2).
9. Castro, A.A., A.I. Cordoves, and P.A. Farias, Determination of the antiretroviral drug acyclovir in diluted alkaline electrolyte by adsorptive stripping voltammetry at the mercury film electrode. Anal Chem Insights, 2013. 8 : p. 21-8.
10. Wei, Y.P., et al., Critical Review of Synthesis, Toxicology and Detection of Acyclovir. Molecules, 2021. 26 (21).
11. De Clercq, E. and G. Li, Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev, 2016. 29 (3): p. 695-747.
12. King, D.H., History, pharmacokinetics, and pharmacology of acyclovir. J Am Acad Dermatol, 1988. 18 (1 Pt 2): p. 176-9.
13. van de Sand, L., et al., Antiviral Active Compounds Derived from Natural Sources against Herpes Simplex Viruses. Viruses, 2021.13 (7).
14. Xu, F., et al., Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr, 2007. 151 (4): p. 374-7.
15. Gonçalves, B.C., et al., Antiviral therapies: advances and perspectives. Fundam Clin Pharmacol, 2021. 35 (2): p. 305-320.
16. Mlynarczyk-Bonikowska, B., et al., Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. Mini Rev Med Chem, 2013. 13 (13): p. 1837-45.
17. Majewska, A. and B. Mlynarczyk-Bonikowska, 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs? Int J Mol Sci, 2022. 23 (7).
18. Coen, D.M. and P.A. Schaffer, Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov, 2003. 2 (4): p. 278-88.
19. Chakrabarty, A., et al., Emerging therapies for herpes viral infections (types 1 - 8). Expert Opin Emerg Drugs, 2004. 9 (2): p. 237-56.
20. Agut, H., et al., Testing the susceptibility of human herpesviruses to antivirals. Future Microbiol, 2009. 4 (9): p. 1111-23.
21. Lehto, J.T., et al., Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant, 2007.26 (1): p. 41-7.
22. Lee, D.H. and R.A. Zuckerman, Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant, 2019. 33 (9): p. e13526.
23. Perera, M.R., M.R. Wills, and J.H. Sinclair, HCMV Antivirals and Strategies to Target the Latent Reservoir. Viruses, 2021.13 (5).
24. Rodriguez, E.M., J.A. Staffa, and D.J. Graham, The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf, 2001. 10 (5): p. 407-10.
25. Humar, A., et al., The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant, 2010. 10 (5): p. 1228-37.
26. Märtson, A.G., et al., Therapeutic Drug Monitoring of Ganciclovir: Where Are We? Ther Drug Monit, 2022. 44 (1): p. 138-147.
27. Takahata, M., et al., Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transpl Infect Dis, 2015. 17 (6): p. 810-5.
28. Paya, C., et al., Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant, 2004. 4(4): p. 611-20.